Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.

P Borchmann; A Engert; A Pluetschow; M Fuchs; J Markova; A Lohri; Z Kral; Richard Greil; M Topp; M Villalobos; J Zijlstra; M Soekler; H Stein; HT Eich; RP Mueller; V Diehl

Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.

P Borchmann
, A Engert
, A Pluetschow
, M Fuchs
, J Markova
, A Lohri
, Z Kral
, Richard Greil
, M Topp
, M Villalobos
, J Zijlstra
, M Soekler
, H Stein
, HT Eich
, RP Mueller
, V Diehl

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	367
Journal	BLOOD
Volume	112
Issue number	11
Publication status	Published - 2008
Event	50th Annual Meeting of American Society of Hematology (ASH) - San Francisco, California, United States Duration: 6 Dec 2008 → 9 Dec 2008

1 Poster

Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.
Borchmann, P., Engert, A., Pluetschow, A., Fuchs, M., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M., Villalobos, M., Zijlstra, J., Soekler, M., Stein, H., Eich, H., Mueller, R. & Diehl, V., 2008.
Research output: Contribution to conference › Poster

Cite this

Borchmann, P., Engert, A., Pluetschow, A., Fuchs, M., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M., Villalobos, M., Zijlstra, J., Soekler, M., Stein, H., Eich, HT., Mueller, RP., & Diehl, V. (2008). Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. BLOOD , 112(11), 367.

Borchmann, P ; Engert, A ; Pluetschow, A et al. / Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. In: BLOOD 2008 ; Vol. 112, No. 11. pp. 367.

@article{ee7f3ca5c3be476d9eed3be234441d1d,

title = "Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.",

author = "P Borchmann and A Engert and A Pluetschow and M Fuchs and J Markova and A Lohri and Z Kral and Richard Greil and M Topp and M Villalobos and J Zijlstra and M Soekler and H Stein and HT Eich and RP Mueller and V Diehl",

year = "2008",

language = "English",

volume = "112",

pages = "367",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

number = "11",

note = "50th Annual Meeting of American Society of Hematology (ASH) ; Conference date: 06-12-2008 Through 09-12-2008",

}

Borchmann, P, Engert, A, Pluetschow, A, Fuchs, M, Markova, J, Lohri, A, Kral, Z, Greil, R, Topp, M, Villalobos, M, Zijlstra, J, Soekler, M, Stein, H, Eich, HT, Mueller, RP & Diehl, V 2008, 'Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.', BLOOD , vol. 112, no. 11, pp. 367.

Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. / Borchmann, P; Engert, A; Pluetschow, A et al.
In: BLOOD , Vol. 112, No. 11, 2008, p. 367.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.

AU - Borchmann, P

AU - Engert, A

AU - Pluetschow, A

AU - Fuchs, M

AU - Markova, J

AU - Lohri, A

AU - Kral, Z

AU - Greil, Richard

AU - Topp, M

AU - Villalobos, M

AU - Zijlstra, J

AU - Soekler, M

AU - Stein, H

AU - Eich, HT

AU - Mueller, RP

AU - Diehl, V

PY - 2008

Y1 - 2008

M3 - Abstract (Journal)

SN - 0006-4971

VL - 112

SP - 367

JO - BLOOD

JF - BLOOD

IS - 11

T2 - 50th Annual Meeting of American Society of Hematology (ASH)

Y2 - 6 December 2008 through 9 December 2008

ER -

Borchmann P, Engert A, Pluetschow A, Fuchs M, Markova J, Lohri A et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. BLOOD . 2008;112(11):367.